Some Biological and Clinical Results from the Investigations of the Chloroethylamines as Anti-Tumour Drugs
1956

Investigating Chloroethylamines as Anti-Tumor Drugs

publication Evidence: moderate

Author Information

Author(s): L. F. Larionov

Primary Institution: Institute of Experimental Pathology and Therapy of Cancer, Academy of Medical Sciences, Moscow, U.S.S.R.

Hypothesis

Can chloroethylamines be effective anti-tumor drugs?

Conclusion

Chloroethylamines, particularly Embichin and its derivatives, show promise in treating Hodgkin's disease and leukemia with fewer side effects compared to traditional therapies.

Supporting Evidence

  • Embichin was found to achieve therapeutic effects while sparing the haemopoietic system.
  • Novoembichin was better tolerated by patients and caused fewer side effects.
  • Lymphochin showed less effectiveness than Embichin and Novoembichin but was well tolerated.
  • Dopan demonstrated strong anti-tumor action in animal models.
  • Sarcolysine was effective against certain human malignant tumors.

Takeaway

Doctors are testing new medicines to help people with cancer, and some of these new medicines work better and are easier on the body than older treatments.

Methodology

The study involved experimental and clinical investigations of chloroethylamines, including Embichin and its derivatives, on cancer patients and animal models.

Limitations

The effectiveness of chloroethylamines on typical malignant tumors was limited, and some patients experienced side effects.

Participant Demographics

Patients with Hodgkin's disease and leukemia were treated, with some studies conducted on rabbits.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication